Table 3 Distribution of treatments according to molecular diagnosis
Molecular diagnosis | Treatment | Distribution | ||
|---|---|---|---|---|
BC | SA | |||
ALK+ | Alectinib | 89.38% | 80% | |
Crizotinib | 10.63% | 20% | ||
EGFR+ | Erlotinib | 15.0% | 0.0% | |
Gefitinib | 30.0% | 30.0% | ||
Afatinib | 15.0% | 5.0% | ||
Osimertinib | 40.0% | 65.0% | ||
ROS1+ | Crizotinib | 100% | 100% | |
WT | TPS 50% | Pembrolizumab | 100% | 100% |
TPS < 50% | Cisp + pmtrx | 30.00% | 40.0% | |
Carb+ paclitx + bev | 10.00% | 5.0% | ||
Cisp + pmtrx + pembro | 60.00% | 55.0% | ||